Metronidazole Basi

Metronidazole, the active ingredient in Metronidazole Basi, is a nitroimidazole antibiotic presented as an intravenous formulation for systemic use. It treats a range of anaerobic bacterial and protozoal infections in adult and pediatric patients where such pathogens are identified.

GNH USA supplies Metronidazole Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metronidazole is indicated for infections caused by anaerobic bacteria and susceptible protozoa. It is employed in several clinical scenarios: - Anaerobic bacterial infections: Reduces bacterial load in mixed anaerobic infections such as intra‑abdominal or pelvic infections. - Trichomoniasis: Eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Giardiasis: Clears Giardia lamblia from the gastrointestinal tract, alleviating diarrhoea and malabsorption. - Clostridioides difficile infection: Controls toxin‑producing C. difficile, helping to resolve colitis and prevent recurrence.

Metronidazole may cause a range of adverse reactions, from mild to severe. Patients should be monitored for any new symptoms during therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient alteration of taste perception. - Headache: occasional mild headache. - Diarrhoea: loose stools that resolve after treatment. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reaction: anaphylaxis, swelling, or difficulty breathing. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Before initiating Metronidazole therapy, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal impairment: Adjust dosing or monitor serum levels in severe renal dysfunction. - Hepatic disease: Use with caution; monitor liver function tests. - Alcohol consumption: Advise patients to avoid alcohol due to disulfiram‑like reaction. - Pregnancy and lactation: Evaluate risk‑benefit; limited data available. - Concomitant neurotoxic drugs: Monitor for additive neuropathy. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metronidazole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Disulfiram: potentiates unpleasant reactions when alcohol is consumed. - Warfarin: may increase anticoagulant effect, raising bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenytoin: may reduce metronidazole levels, decreasing effectiveness. - Alcohol: concurrent use can cause severe nausea, vomiting, and flushing.